|
If you are experiencing a medical emergency, contact your healthcare professional or, in the US, dial 911.
For clinical and technical information or to report an adverse drug event involving a Talecris product, please contact Talecris Clinical Communications at 1-800-520-2807.
For customer service and questions about reimbursement please call Prolastin Direct at 1-800-305-7881 during business hours, 7 AM - 6 PM Central Standard Time.
For reimbursement questions, call 1-800-288-8374.
In addition to Talecris resources, you may want to contact the Plasma Protein Therapeutics Association (PPTA): the PPTA Patient Notification System is a free, confidential, 24-hour communication system that provides information, in English and French, on plasma-derived and recombinant product withdrawals and recalls. To enroll, go to
www.patientnotificationsystem.org.
To submit questions and comments that are not related to an adverse event, please input your contact information in the following form. Please be assured that personal information submitted in this form will be kept confidential and will only be used to respond to your request. For more on Talecris' privacy policy, please read our Privacy Statement before providing your personal information.
At Prolastin.com we welcome your questions and comments, and invite you to contact us by using the form below.
*Indicates required information.
Required information is missing. Please review the fields below and complete the required information.
*Required information
To best serve your needs, and based upon the nature of your inquiry, we may need to speak with you as soon as possible.
Please be assured that personal information submitted in this form will be kept confidential and will only be used to respond to your request. For more details on Talecris' privacy statement, please read our Privacy Statement.
If you have questions or comments about other Talecris products, or about our company, please click here.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|